Physician profile
Theresia Zuh Tabe
NPI 1861038234
$10,510.69
in general payments reported to CMS, 2019-2025
29 companies · $2,546 in 2025
The $2,546 reported for 2025 was more than what 97% of Psychiatric/Mental Health, Adult (Registered Nurse) providers received nationally (typical 2025 total: $121).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $692 · 2022: $1,816 · 2023: $3,218 · 2024: $2,239 · 2025: $2,546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,975 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,975.49 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,642.04 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $1,555.00 | 2021-2025 | |
| Alkermes, INC. | $1,485.09 | 2022-2025 | Lybalvi, Aristada, Vivitrol |
| Corium, LLC | $541.82 | 2021-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $539.77 | 2022-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $536.14 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $467.21 | 2022-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $466.88 | 2022-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $447.22 | 2022-2025 | Rexulti |
| Almatica Pharma LLC | $404.78 | 2023-2025 | Loreev Xr, Sertraline Hcl |
| Teva Pharmaceuticals USA, INC. | $379.31 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Tris Pharma INC | $364.77 | 2022-2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $234.13 | 2021-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $213.48 | 2022-2024 | Spravato |
| Merck Sharp & Dohme LLC | $171.68 | 2022-2023 | Belsomra |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $158.18 | 2022-2025 | Wellbutrin, Aplenzin |
| Neos Therapeutics, Lp | $137.78 | 2021-2025 | Adzenys Xr-Odt |
| Noven Therapeutics, LLC | $137.19 | 2023-2025 | Secuado, Xelstrym |
| Harmony Biosciences LLC | $112.16 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $102.77 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $70.48 | 2025 | |
| Idorsia Pharmaceuticals US INC | $65.03 | 2023 | Quviviq |
| Ironshore Pharmaceuticals INC. | $62.75 | 2023 | Jornay Pm |
| Inspire Medical Systems, INC. | $61.52 | 2023-2024 | Inspire |
| Eisai INC. | $44.66 | 2021-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $39.79 | 2022 | |
| Jazz Pharmaceuticals INC. | $30.00 | 2025 | |
| Indivior INC. | $20.70 | 2025 | Sublocade |
| Collegium Pharmaceutical, INC. | $18.36 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theresia Tabe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.